Fig. 5.

Immunogenicity of conjugates synthesized by the two different methods. a Comparison of serum anti-Pfs230 antibody titer of Pfs230-OMPC conjugates synthesized by method 1 (Pfs230-OMPC-2), method 2 (Pfs230-OMPC-5) and Pfs230-EPA assayed on day 42 and day 188. Mice were immunized on days 0 and 28 at 0.5 µg dose with conjugates formulated in AdjuPhos^®. b Anti-Pfs230 antibody titer of Pfs230-OMPC-2, Pfs230-OMPC-5, and Pfs230-EPA at different time points up to day 188, assessing the durability of immune response. c Reduction in the midgut oocyst count of mosquitos fed on the immune sera from mice vaccinated with the above three conjugates on days 42 and 188, compared to mosquitos fed on control sera, assayed by SMFA for functional activity. d Table listing the functional activity (TRA and prevalence) of the three conjugates, along with their titer. Error bars represent 95% confidence limit of the geometric mean. Statistical differences between groups were measured using a Kruskal–Wallis one-way ANOVA followed by a Dunn multiple comparator test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001